FANCD2 and glioblastoma: Tissue microarray analysis showed that upregulation of FANCD2 is positively associated with tumor size and adverse prognosis in breast cancer [8,9,10], ovarian cancer [11,12], nasopharyngeal carcinoma [13], glioblastoma [14], and endometrial carcinoma [15].